Biodexa Pharmaceuticals Plc Overview
Pro stress-test →Biodexa Pharmaceuticals is a clinical-stage biopharmaceutical company developing a pipeline of products for the treatment of diseases with unmet medical needs. Founded in 2000 and headquartered in Cardiff, the United Kingdom, the company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023.
Strategic Profile
Pro stress-test →The company focuses on a clinical-stage biopharmaceutical pipeline focused on gastrointestinal cancers, rare diseases and other unmet medical needs, with programs including eRapa for familial adenomatous polyposis and non-muscle invasive bladder cancer, MTX240 for gastrointestinal stromal tumors, and tolimidone for type 1 diabetes. The company also offers drug delivery platforms including Q-Sphera, MidaSolve, and MidaCore nanoparticle technologies.
Competitive Landscape
Pro stress-test →Biodexa operates as a drug delivery technology company focused on research and development of medicines for rare cancers through both in-house programs and partnered programs. It competes in the rare disease and oncology sectors against established pharmaceutical companies developing therapies for similar indications.
Industry Context
Biodexa Pharmaceuticals Plc operates in Biopharmaceutical / Rare Disease Oncology.
Key facts
Founded: 2000 · Headquarters: Cardiff, UK · Employees: ~11 · Revenue: $1.1M (2026 est.) · Market cap: Up to $300 million (micro-cap)